ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 6,672 shares, a decline of 50.1% from the September 15th total of 13,369 shares. Based on an average trading volume of 44,566 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the shares of the company are sold short.
ALPS Medical Breakthroughs ETF Trading Down 0.8%
Shares of NYSEARCA:SBIO traded down $0.41 during trading on Wednesday, hitting $51.23. 28,667 shares of the company were exchanged, compared to its average volume of 38,516. The stock has a 50 day moving average of $63.47 and a 200 day moving average of $59.49. ALPS Medical Breakthroughs ETF has a 52-week low of $41.22 and a 52-week high of $70.85.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in SBIO. Harbor Investment Advisory LLC bought a new stake in shares of ALPS Medical Breakthroughs ETF during the second quarter valued at about $29,000. Fulcrum Equity Management purchased a new stake in shares of ALPS Medical Breakthroughs ETF in the second quarter worth about $263,000. Rhodes Investment Advisors Inc. ADV bought a new position in shares of ALPS Medical Breakthroughs ETF in the third quarter valued at approximately $266,000. Independent Financial Group LLC bought a new position in shares of ALPS Medical Breakthroughs ETF in the first quarter valued at approximately $283,000. Finally, Kestra Advisory Services LLC boosted its position in shares of ALPS Medical Breakthroughs ETF by 27.6% in the first quarter. Kestra Advisory Services LLC now owns 8,186 shares of the company’s stock valued at $428,000 after acquiring an additional 1,772 shares during the period.
About ALPS Medical Breakthroughs ETF
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Further Reading
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
